Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM

September 30, 2021 Auto Bot Casirivimab, Clinical Trials, Imdevimab, NEJM, P-III, REGEN-COV, Regeneron, Trial 0

Shots:

  • The P-III trial evaluates the efficacy and safety of REGEN-COV (casirivimab and imdevimab, 1200/2400mg) vs PBO in a non-hospitalized patient with COVID-19
  • The trial met its 1EPs & 2EPs i.e., 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients & the safety profile was consistent with a previously reported data
  • Additionally, multiple analyses showed that the Ab cocktail retains potency against the variants of concern circulating within the US. REGEN-COV is available for free to eligible patients in the US as part of a US government-funded program

Click here to­ read full press release/ article | Ref: PR Newswire | Image: The Print

The post Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM first appeared on PharmaShots.